At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
In Brief
A Phase 3 clinical trial evaluating Teclistamab, Pomalidomide, and 3 other interventions for Relapsed or Refractory Multiple Myeloma. Active but no longer recruiting, targeting 614 participants across 211 sites in 24 countries.
Detailed Summary
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Study Details
Timeline
Interventions
Teclistamab will be administered subcutaneously.
Pomalidomide will be administered orally.
Bortezomib will be administered subcutaneously.
Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
Carfilzomib will be administered intravenously.